Conference Correspondent  - ASCO 2021 - Breast Cancer

Women whose genetic makeup includes certain gene variants have an increased risk of developing breast and ovarian cancer. However, genetic testing is not considered standard of care at the time of diagnosis of breast cancer. Typically, only women who meet a distinct set of criteria established by the National Comprehensive Cancer Network (NCCN) are referred for genetic testing. As a result, many women diagnosed with breast cancer may miss the opportunity for individualized therapies and risk management.

Researchers evaluated demographic and clinical factors associated with rates of eligibility and referrals for genetic testing, completion of appointments by the patients, and the outcomes of the assessment if completed among women previously diagnosed with breast cancer. Investigators obtained the medical records of 150 women who received care at the Karmanos Cancer Institute from January 2018 to December 2018. The average age of the women at the time of diagnosis was 57.1 years.

Eligibility for genetic testing was determined by NCCN guidelines. Among the 150 women whose medical records were evaluated, 60.7% were eligible for genetic testing and 46.2% of these patients completed the assessment. In general, eligible women tended to be younger (52.6 years old), white (75%), have Medicaid or private insurance (75% and 72.9%, respectively), and diagnosed with stage I-III disease (67.8%). Referrals for genetic testing were 3.5 times more common among women who met NCCN benchmarks.

Of the patients who had a genetic counseling appointment (59.3%), 78.0% kept the appointment. Results from the study indicate women diagnosed with stage IV breast cancer and those with Medicaid or private insurance were more likely to present for the appointment than those with stage I-III disease or Medicare. There does not appear to be any differences in appointment completion associated with race. The majority (95.9%) of women who attended their appointment also completed genetic counseling. Among these women, 8.5% had a gene variant associated with breast cancer.

The researchers conclude that lack of genetic counseling referrals contribute to a gap between the need for and completion of genetic testing. Fewer referrals exclude certain populations of women with breast cancer from genetic testing. Improving access to genetic counseling may increase identification of specific genetic variants that can be targeted for more personalized treatment plans among these patients.

Source: Wehbe A, Manning MA, Assad H, et al. Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer. American Society of Clinical Oncology Virtual Meeting; June 4-8, 2021. Abstract 10524.

Related Items
Inflammatory Responses to Neoadjuvant Chemotherapy Can Be Regulated by Moderate Physical Exercise Prior to Surgery
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Assessment of Factors That Influence Psychosocial Function in Breast Cancer Patients After Treatment
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Identification of Biomarkers for HER2-Negative Advanced Breast Cancer Is Influenced by Race: A Real-World Study
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Treatment with Alpelisib plus Fulvestrant Achieves Long-Term Disease Control in Endocrine-Resistant (HR-Positive/HER2-Negative) Advanced Breast Cancer
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Behavioral Interventions Demonstrate Improved Long-Term Adherence to Adjuvant Endocrine Therapy Among Women with HR-Positive Breast Cancer
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Assessment of Oncology Patient Satisfaction with Telehealth Visits
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Need for Improved Access to Cancer Screening Tools for Minorities with Socioeconomic Barriers to Medical Care
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Novel and Clinically Relevant Measure of Perceived Fatigability Reveals Benefit of Exercise in Breast Cancer Survivors
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Association of Stage of Breast Cancer Diagnosis and Socioeconomic Status in French Women
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Alpelisib Overcomes Resistance to CDK4/6 Inhibitors in HR-Positive/HER2-Negative Advanced Breast Cancer Patients
Conference Correspondent  published on June 7, 2021 in ASCO 2021 - Breast Cancer
Last modified: July 22, 2021